Physician profile
Omid S Shaye
NPI 1861611931
$7,659.85
in general payments reported to CMS, 2019-2025
72 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $404 · 2021: $739 · 2022: $1,151 · 2023: $1,740 · 2024: $1,245 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,442 · Education: $70.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,441.83 |
| Education | $70.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $469.90 | 2022-2025 | Dupixent, Libtayo |
| Pfizer INC. | $457.00 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $443.09 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Astrazeneca Pharmaceuticals LP | $425.21 | 2019-2025 | Enhertu, Calquence, Tagrisso |
| Janssen Biotech, INC. | $388.26 | 2019-2025 | Darzalex, Tecvayli, Stelara |
| Seagen INC. | $340.37 | 2019-2023 | Adcetris, Tukysa |
| Astellas Pharma US INC | $331.27 | 2023-2025 | Xospata, Vyloy, Padcev |
| Adc Therapeutics America, INC. | $264.92 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $260.99 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $207.96 | 2020-2023 | Xpovio |
| Genzyme Corporation | $192.92 | 2020-2023 | |
| Lilly USA, LLC | $172.87 | 2019-2023 | Verzenio |
| Celgene Corporation | $170.73 | 2019-2025 | Reblozyl, Pomalyst |
| Incyte Corporation | $162.45 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Emd Serono, INC. | $162.25 | 2022-2025 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omid Shaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.